mTOR inhibitors in cancer therapy

被引：259

作者：

Zaytseva, Yekaterina Y. ^{[1
]}

Valentino, Joseph D. ^{[1
,2
]}

Gulhati, Pat ^{[3
]}

Evers, B. Mark ^{[1
,2
]}

机构：

[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA

[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA

[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA

来源：

CANCER LETTERS | 2012年 / 319卷 / 01期

关键词：

mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;

D O I：

10.1016/j.canlet.2012.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 7

页数：7

共 50 条

[41] Clinical development of mTOR inhibitors in breast cancer
Vicier, Cecile
Dieci, Maria Vittoria
Arnedos, Monica
Delaloge, Suzette
Viens, Patrice
Andre, Fabrice
BREAST CANCER RESEARCH, 2014, 16 (01):
[42] Clinical development of mTor inhibitors for renal cancer
Ghidini, Michele
Petrelli, Fausto
Ghidini, Antonio
Tomasello, Gianluca
Hahne, Jens Claus
Passalacqua, Rodolfo
Barni, Sandro
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1229 - 1237
[43] Cancer and mTOR inhibitors in kidney transplantation recipients
Kao, Chih-Chin
Liu, Jia-Sin
Chang, Yu-Kang
Lin, Ming-Huang
Lin, Yen-Chung
Chen, Hsi-Hsien
Chang, Wei-Chiao
Hsu, Chih-Cheng
Wu, Mai-Szu
PEERJ, 2018, 6
[44] Sunitinib, sorafenib and mTOR inhibitors in renal cancer
Radulovic, Sinisa
Bjelogrlic, Snezana K.
JOURNAL OF BUON, 2007, 12 : S151 - S162
[45] Clinical development of mTOR inhibitors in breast cancer
Cecile Vicier
Maria Vittoria Dieci
Monica Arnedos
Suzette Delaloge
Patrice Viens
Fabrice Andre
Breast Cancer Research, 16
[46] Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis
Sivendran, Shanthi
Ying, Jian
Gartrell, Benjamin Adam
Agarwal, Neeraj
Boucher, Kenneth M.
Choueiri, Toni K.
Sonpavde, Guru
Oh, William K.
Galsky, Matt D.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
[47] Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy
Ghareghomi, Somayyeh
Atabaki, Vahideh
Abdollahzadeh, Naseh
Ahmadian, Shahin
Ghoran, Salar Hafez
ADVANCED PHARMACEUTICAL BULLETIN, 2023, 13 (01) : 24 - 35
[48] Synthetic lethality of KDM1A and mTOR inhibitors: A novel combination therapy for endometrial cancer
Pitta-Venkata, Prabhakar
Palacios, Bridgitte
Chen, Yihong
Viswanadhapalli, Suryavathi
Pratap, Uday P.
Luo, Yiliao
Li, Mengxing
Altwegg, Kristin
Li, Xiaonan
Suzuki, Takayoshi
Tekmal, Rajeshwar Rao
Kost, Edward
Sareddy, Gangadhara Reddy
CANCER RESEARCH, 2019, 79 (13)
[49] Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors
Mollica, Veronica
Maggio, Ilaria
Lopez-Beltran, Antonio
Montironi, Rodolfo
Cimadamore, Alessia
Cheng, Liang
Rizzo, Alessandro
Giunchi, Francesca
Schiavina, Riccardo
Fiorentino, Michelangelo
Brunocilla, Eugenio
Massari, Francesco
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (09) : 755 - 763
[50] Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
Faes, Seraina
Santoro, Tania
Demartines, Nicolas
Dormond, Olivier
CANCERS, 2017, 9 (11):

← 1 2 3 4 5 →